Show simple item record

dc.contributor.authorDe Vivo, Immaculata
dc.contributor.authorHankinson, Susan Elizabeth
dc.contributor.authorColditz, Graham A.
dc.contributor.authorHunter, David J.
dc.date.accessioned2011-04-29T04:32:48Z
dc.date.issued2004
dc.identifier.citationDe Vivo, Immaculata, Susan E. Hankinson, Graham A. Colditz, and David J. Hunter. 2004. The progesterone receptor Val660→Leu polymorphism and breast cancer risk. Breast Cancer Research 6(6): R636-R639.en_US
dc.identifier.issn1465-5411en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:4879209
dc.description.abstractBackground: Recent evidence suggests a role for progesterone in breast cancer development and tumorigenesis. Progesterone exerts its effect on target cells by interacting with its receptor; thus, genetic variations, which might cause alterations in the biological function in the progesterone receptor (PGR), can potentially contribute to an individual's susceptibility to breast cancer. It has been reported that the PROGINS allele, which is in complete linkage disequilibrium with a missense substitution in exon 4 (G/T, valine→leucine, at codon 660), is associated with a decreased risk for breast cancer. Methods: Using a nested case-control study design within the Nurses' Health Study cohort, we genotyped 1252 cases and 1660 matched controls with the use of the Taqman assay. Results: We did not observe any association of breast cancer risk with carrying the G/T (Val660→Leu) polymorphism (odds ratio 1.10, 95% confidence interval 0.93–1.30). In addition, we did not observe an interaction between this allele and menopausal status and family history of breast cancer as reported previously. Conclusion: Overall, our study does not support an association between the Val660→Leu PROGINS polymorphism and breast cancer risk.en_US
dc.language.isoen_USen_US
dc.publisherBioMed Centralen_US
dc.relation.isversionofdoi:10.1186/bcr928en_US
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064075/pdf/en_US
dash.licenseLAA
dc.subjectbreast canceren_US
dc.subjectlinkage disequilibriumen_US
dc.subjectpolymorphismen_US
dc.subjectprogesterone receptoren_US
dc.titleThe progesterone receptor Val660→Leu polymorphism and breast cancer risken_US
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden_US
dc.relation.journalBreast Cancer Researchen_US
dash.depositing.authorDe Vivo, Immaculata
dc.date.available2011-04-29T04:32:48Z
dash.affiliation.otherSPH^Epidemiologyen_US
dash.affiliation.otherHMS^Medicine-Brigham and Women's Hospitalen_US
dash.affiliation.otherSPH^Epidemiologyen_US
dash.affiliation.otherHMS^Medicine-Brigham and Women's Hospitalen_US
dash.affiliation.otherSPH^Epidemiologyen_US
dash.affiliation.otherHMS^Ophthalmologyen_US
dc.identifier.doi10.1186/bcr928*
dash.contributor.affiliatedColditz, Graham
dash.contributor.affiliatedHankinson, Susan
dash.contributor.affiliatedHunter, David
dash.contributor.affiliatedDe Vivo, Immaculata


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record